Prospective, case-control study of serological response after two doses of BNT162b2 anti-SARS-CoV-2 mRNA vaccine in transfusion-dependent thalassemic patients

Sgherza, Nicola; Zucano, Stefania; Vitucci, Angelantonio; Palma, Antonio; Tarantini, Francesco; Campanale, Daniela; Vimercati, Luigi; Larocca, Angela Maria Vittoria; Visceglie, Domenico; Acquafredda, Amalia; Ostuni, Angelo; Gennaro, Daniela Di; Vitucci, Carmen; Tafuri, Silvio; Musto, Pellegrino

doi:10.4084/mjhid.2022.056

Cited by 1 publication

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They concluded that the vaccine was well tolerated and induced a serological response in all patients with TDT (although it did not completely protect against SARS-CoV-2 infection) but at a lower magnitude than healthy controls. They also observed rapid resolution of symptoms in those who developed infection postvaccination [19]. Our study also revealed that the vaccine was not completely protective and that the disease course was mild in the 11 patients who got infected, none of whom required hospitalization.…”

Section: Discussionmentioning

confidence: 66%

Adverse Effects of COVID-19 Vaccination in Patients with Transfusion-Dependent Thalassemia: An Observational Study from a Tertiary Care Center in Punjab, India

Kakkar¹,

Jain²,

Jain³

et al. 2023

Acta Haematol

View full text Add to dashboard Cite

Vaccination against SARS-CoV2 is the most important weapon in the arsenal in the battle against COVID-19. There is concern about an increased risk of adverse effects in patients with transfusion-dependent thalassemia (TDT), which affects vaccine acceptance. A predesigned questionnaire was used to evaluate adverse effects (local/systemic within 90 days after vaccination) in participants >18 years of age with TDT. A total of 100 patients received 129 vaccine doses. The mean age of the patients was 24.3 ± 5.7 years and M: F ratio of 1.6:1. Covishield (Serum Institute of India) was administered to 89% of the participants and Covaxin (Bharat Biotech Limited) to 11% of the participants. Adverse effects were documented in 62% of the respondents and were more pronounced after the first dose (52%) compared to the second dose (9%). The most frequent adverse effects were pain at the injection site (43%) and fever (37%). All adverse effects were mild and none of the participants required hospitalization. There were no differences in adverse effects among different vaccines, the presence or absence of comorbidities, blood groups, or ferritin levels. The SARS-CoV2 vaccine appears to be safe in patients with TDT.

show abstract

Section: Discussionmentioning

confidence: 66%